“Among several commercial services who have claimed to be specialized to generate mouse models with genetic modifications, I recognize that Cyagen is one of the best. We are looking forward to having more cooperation with them.”Korea Brain Research Institute (KBRI)
영업일 기준 1-2일 내에 답변해 드리겠습니다.
Strain Background: C57BL/6N
The hPD-1 has been developed by inserting, within the mouse PD-1 locus, a chimeric PD-1 with a human extracellular domain, a murine transmembrane domain and a murine intracellular domain. The design of the TIM3 humanized model, developed by knockin at the mouse TIM3 locus, enables the expression of a chimeric TIM3 with a human extracellular domain, a murine transmembrane domain and a murine intracellular domain. The double-humanized PD-1 and TIM3 mouse model (hPD-1/hTIM3) was generated by intercrossing hPD-1 and hTIM3 mice.
The hPD-1/hTIM3 mouse enables the in vivo efficacy and safety assessment of compounds targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.
Figure 1. hPD-1 and hTIM3 expression on tumor-infiltrated CD8 T cells. Human TIM3 and human PD-1 expression on CD8 T cells isolated from tumor. Tumors were harvested 28 days post inoculation of MC38 cells in hPD-1/hTIM3 mice. Isolated cells were pregated on lymphocytes, single cells, living cells, CD45+/TCRb+, and CD8+.
Figure 2. Anti-human TIM3 therapy in combination with anti-human PD-1 improves tumor protection when compared to vehicle or blocking PD-1 only. Survival of hPD-1/hTIM3 mice implanted subcutaneally with MC38 cells and treated with vehicle, αhPD-1, or αhPD-1+αhTIM3.